Literature DB >> 17580276

Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.

Yuji Sakuma1, Shoichi Matsukuma, Mitsuyo Yoshihara, Yoshiyasu Nakamura, Kazumasa Noda, Haruhiko Nakayama, Yoichi Kameda, Eiju Tsuchiya, Yohei Miyagi.   

Abstract

Although adenocarcinomas of the lung are associated with epidermal growth factor receptor (EGFR) gene mutations and sensitivity to EGFR tyrosine kinase inhibitors, it remains unclear whether bronchioloalveolar carcinoma (BAC) components and/or subtypes affect these associations. We aimed to clarify correlations between EGFR gene mutations and BAC components and to establish the histologic features as reliable predictors for the mutations. We examined 141 non-small cell lung cancers (NSCLCs), including 118 adenocarcinomas, for mutations in exons 19 and 21 of the EGFR gene together with mutations in codon 12 of the K-ras gene using loop-hybrid mobility shift assays, a highly sensitive polymerase chain reaction-based method. Adenocarcinomas were subdivided into subtypes with a nonmucinous or mucinous BAC component and those without BAC components. In NSCLCs, EGFR mutations were detected in 75 cases (53.2%) and were significantly associated with adenocarcinoma, female sex, and never smoking. Among adenocarcinomas, nonmucinous and mucinous BAC components were significantly associated with EGFR and K-ras gene mutations, respectively. Because EGFR mutations were detected even in most pure nonmucinous BACs, ie, lung adenocarcinoma in situ, EGFR mutation is considered a critical event in the pathogenesis of nonmucinous BAC tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17580276     DOI: 10.1309/WVXFGAFLAUX48DU6

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  31 in total

1.  GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.

Authors:  Lauren L Ritterhouse; Marina Vivero; Mari Mino-Kenudson; Lynette M Sholl; A John Iafrate; Valentina Nardi; Fei Dong
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

Review 2.  Epidermal growth factor receptor in non-small cell lung cancer.

Authors:  Charles N Prabhakar
Journal:  Transl Lung Cancer Res       Date:  2015-04

3.  Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.

Authors:  Yang Zhang; Yihua Sun; Yunjian Pan; Chenguang Li; Lei Shen; Yuan Li; Xiaoyang Luo; Ting Ye; Rui Wang; Haichuan Hu; Hang Li; Lei Wang; William Pao; Haiquan Chen
Journal:  Clin Cancer Res       Date:  2012-02-08       Impact factor: 12.531

4.  DNA methylation profile during multistage progression of pulmonary adenocarcinomas.

Authors:  Jin-Haeng Chung; Hyun Ju Lee; Baek-Hui Kim; Nam-Yun Cho; Gyeong Hoon Kang
Journal:  Virchows Arch       Date:  2011-04-15       Impact factor: 4.064

5.  Lesions in patients with multifocal adenocarcinoma are more frequently in the right upper lobes.

Authors:  Hiroyuki Kaneda; Yoshiko Uemura; Takahito Nakano; Yohei Taniguchi; Tomohito Saito; Toshifumi Konobu; Yukihito Saito
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-06-24

6.  Expression level of CRKL and AXL combined with exon 19 deletion in EGFR and ALK status confer differential prognosis of lung adenocarcinoma subtypes.

Authors:  Yi-Ran Cai; Yu-Jie Dong; Hong-Bo Wu; Da-Ping Yu; Li-Juan Zhou; Dan Su; Li Zhang; Xue-Jing Chen
Journal:  Oncol Lett       Date:  2016-09-02       Impact factor: 2.967

Review 7.  Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.

Authors:  Jody C Chuang; Joseph B Shrager; Heather A Wakelee; Joel W Neal
Journal:  Clin Ther       Date:  2016-06-29       Impact factor: 3.393

8.  Metabolic profiling identifies lung tumor responsiveness to erlotinib.

Authors:  Teresa W-M Fan; Andrew N Lane; Richard M Higashi; Michael Bousamra; Goetz Kloecker; Donald M Miller
Journal:  Exp Mol Pathol       Date:  2009-05-03       Impact factor: 3.362

9.  Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.

Authors:  Marie Brevet; Maria Arcila; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2010-01-21       Impact factor: 5.568

10.  Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.

Authors:  Taro Ohba; Gouji Toyokawa; Takuro Kometani; Kaname Nosaki; Fumihiko Hirai; Masafumi Yamaguchi; Motoharu Hamatake; Takashi Seto; Yukito Ichinose; Kenji Sugio
Journal:  Surg Today       Date:  2013-04-23       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.